Scientists running the Com-COV study looking at different COVID-19 vaccine combinations are reporting their first results on immunogenicity from the trial, which looked at mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca vaccines given four weeks apart.
Journalists dialled in to this briefing to hear the Chief Investigator on the trial, Professor Matthew Snape, describe and explain the results.
Please note this data is a preprint, so it is early work that has not yet been through peer-review and is not published in a journal.
Prof Matthew Snape, Associate Professor in Paediatrics and Vaccinology, University of Oxford, Chief Investigator on the trial
This Briefing was accompanied by an SMC Roundup of Comments.